Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer

被引:0
作者
Zhuanglin Li
Mingxue Wang
Deling Yu
Wenting Luo
Jianmin Fang
Changjiang Huang
Xuejing Yao
机构
[1] RemeGen,School of Life Science and Technology
[2] Ltd.,undefined
[3] Mabplex International Ltd.,undefined
[4] Tongji University,undefined
来源
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词
Epidermal growth factor receptor; Non-small cell lung cancer; Monoclonal antibody; Antibody–drug conjugates;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:61 / 72
页数:11
相关论文
共 105 条
[1]  
Schrank Z(2018)Current molecular-targeted therapies in NSCLC and their mechanism of resistance Cancers (Basel) 10 1-17
[2]  
Chhabra G(2004)Select clinical trials of erlotinib (OSI-774) in non-small cell lung cancer with emphasis on phase III outcomes Clin Lung Cancer 6 S24-29
[3]  
Lin L(2004)Multidisciplinary management of lung cancer N Engl J Med 350 379-392
[4]  
Fuster LM(2012)Treatment of lung cancer Radiol Clin N Am 50 961-974
[5]  
Sandler AB(2001)Untangling the ErbB signaling network Nat Rev Mol Cell Biol 2 127-137
[6]  
Spira A(2006)Epidermal growth factor receptor targeting in cancer Semin Oncol 33 369-385
[7]  
Ettinger DS(2003)Epidermal growth factor receptor: mechanisms of activation and signaling Exp Cell Res 284 31-53
[8]  
Gadgeel SM(2013)Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy J Cancer 4 736-754
[9]  
Ramalingam SS(2006)Ras, PI(3)K and mTOR signalling controls tumor cell growth Nature 441 424-430
[10]  
Kalekerian GP(2000)Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression Oncol Rep 7 603-607